It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
Hemorrhagic shock (HS), which causes insufficient tissue perfusion, can result in multiple organ failure (MOF) and death. This study aimed to evaluate whether doxycycline (DOX) protects cardiovascular, kidney, and liver tissue from damage in a rat model of HS. Immediately before the resuscitation, DOX (10 mg/kg; i.v.) was administered, and its protective effects were assessed 24 h later. Mean arterial pressure, renal blood flow, heart rate, vasoactive drug response, and blood markers such as urea, creatinine, AST, ALT, CPK, CPR, and NOx levels were determined.
Results
We showed that DOX has a significant effect on renal blood flow and on urea, creatinine, AST, ALT, CPK, and NOx. Morphologically, DOX reduced the inflammatory process in the liver tissue.
Conclusions
We conclude that DOX protects the liver and kidney against injury and dysfunction in a HS model and could be a strategy to reduce organ damage associated with ischemia-and-reperfusion injury.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Universidade Federal de Santa Catarina, Department of Pharmacology, Graduate Program in Pharmacology, Florianópolis, Brazil (GRID:grid.411237.2) (ISNI:0000 0001 2188 7235); Universidade Estadual de Ponta Grossa, Department of Structural Biology, Molecular and Genetics, Post Graduation Program in Biomedical Science, Ponta Grossa, Brazil (GRID:grid.412323.5) (ISNI:0000 0001 2218 3838)
2 Universidade Estadual de Ponta Grossa, Department of Structural Biology, Molecular and Genetics, Ponta Grossa, Brazil (GRID:grid.412323.5) (ISNI:0000 0001 2218 3838)
3 Universidade Federal de Santa Catarina, Department of Pharmacology, Graduate Program in Pharmacology, Florianópolis, Brazil (GRID:grid.411237.2) (ISNI:0000 0001 2188 7235)
4 Universidade Estadual de Ponta Grossa, Department of Clinical and Toxicological Analysis, Ponta Grossa, Brazil (GRID:grid.412323.5) (ISNI:0000 0001 2218 3838)
5 Universidade Estadual de Ponta Grossa, Department of Structural Biology, Molecular and Genetics, Post Graduation Program in Biomedical Science, Ponta Grossa, Brazil (GRID:grid.412323.5) (ISNI:0000 0001 2218 3838)